

An AACR Special Conference on

EMT and Cancer Progression and Treatment

Conference Program

Sunday, February 28

6:30 p.m.-8:00 p.m. Keynote Session

6:30 EMT under review
Jean Paul Thiery
Institute of Molecular and Cell Biology, Singapore

7:15 EMT and angiogenesis in cancer metastasis
Eric G. Neilson
Vanderbilt University, Nashville, TN

**8:15 p.m.-10:15 p.m. Poster Session A and
Welcome Dessert Reception**

Monday, March 1

7:00 a.m.-8:00 a.m. Continental Breakfast

8:00 a.m.-10:00 a.m. Session 1
EMT and MET in Normal Development
*Chairperson: Paolo M. Comoglio, Institute for Cancer
Research-Candiolo, Torino, Italy*

**8:00 SoxB transcription factors control Snail expression and EMT in
developing embryos and cancer cells**
M. Angela Nieto, Instituto de Neurociencias, Alicante, Spain

8:30 Regulation of EMT by integrins
Harold A. Chapman, University of California, San Francisco, CA

9:00 The role of EMT and EndMT in cancer progression and fibrosis
Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA

9:30 Developmental EMTs as a model for pathological EMTs
Carole B. LaBonne, Northwestern University, Evanston, IL

10:00 a.m.-10:30 a.m. Coffee Break

10:30 a.m.-12:30 p.m. Session 2
EMT and MET in Cancer Development
Chairperson: M. Angela Nieto, Instituto de Neurociencias, Alicante, Spain

10:30 The Six1 homeoprotein as a regulator of TGF- β signaling, EMT, and cancer stem cells
Heide L. Ford, University of Colorado Denver and Health Science Program, Aurora, CO

11:00 Tumor invasion and metastasis: EMT and cancer stem cells
Thomas Brabletz, University of Freiburg, Freiburg im Breisgau, Germany

11:30 Insights into the human breast cancer EMT from established cell line
Erik W. Thompson, St. Vincent's Hospital, Fitzroy, Australia

12:00 Evidence for linking EMT to clinical outcome: E-cadherin expression in non-small cell lung cancer (NSCLC) predicts clinical benefits from erlotinib therapy
David W. Sternberg, OSI Pharmaceuticals, Inc., Farmingdale, NY

12:30 p.m.-2:00 p.m. Lunch on own

2:00 p.m.-4:00 p.m. Session 3
Signals Inducing EMT
Chairperson: Margaret C. Frame, University of Edinburgh, Edinburgh, Scotland

2:00 Targeting invasion and metastasis
Margaret C. Frame

2:30 Invasive growth: A genetic program driven by the MET oncogene
Paolo M. Comoglio, Institute for Cancer Research-Candiolo, Torino, Italy

3:00 Actions of angiogenesis inhibitors on tumor blood vessels and tumor cells
Donald M. McDonald, University of California, San Francisco, CA

3:30 The T-box transcription factor Brachyury induces epithelial-to-mesenchymal transition in human epithelial tumor cells*
Romaine I. Fernando, Center for Cancer Research, National Cancer Institute, Bethesda, MD

3:45 Comparison of in vitro and in vivo epithelial-to-mesenchymal transition following inducible expression of Snail or Zeb-1 in a human non-small cell lung cancer line*
Maryland Rosenfeld-Franklin, OSI Pharmaceuticals, Melville, NY

4:00 p.m.-4:30 p.m. Coffee Break

4:30 p.m.-6:30 p.m. Session 4
Signaling Pathways Driving EMT
Chairperson: Donald M. McDonald, University of California, San Francisco, CA

4:30 The tumor suppressor pathways TGF- β and LKB1 control EMT
Aristidis Moustakas, Ludwig Institute for Cancer Research, Uppsala, Sweden

5:00 The Cain and Abl of EMT and TGF- β signaling in mammary epithelial cells
William P. Schiemann, University of Colorado Denver, Aurora, CO

5:30 FGFR1 and Wnt-mediated EMT and stem cell proliferation
David M. Spencer, Baylor College of Medicine, Houston, TX

6:00 Circulating tumor cells from patients with metastatic breast and prostate cancer express vimentin and n-cadherin*
Andrew J. Armstrong, Duke University, Durham, NC

6:15 The Src tyrosine kinase downregulates C/EBP delta protein expression via the SIAH2 E3 ubiquitin ligase to maintain motility of breast tumor cells*
Tapasree Roy Sarkar, National Cancer Institute, Bethesda, MD

6:30 p.m.-8:30 p.m. Poster Session B and Reception

Tuesday, March 2

7:30 a.m.-8:00 a.m. Continental Breakfast

8:00 a.m.-10:00 a.m. Session 5
EMT in Invasion and Metastasis
Chairperson: Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA

8:00 Molecular mechanisms of EMT contributing to invasion and metastasis in breast tumors
John S. Condeelis, Albert Einstein College of Medicine, Bronx, NY

8:30 The role of alternate isoforms in EMT and metastasis
Frank B. Gertler, MIT, Cambridge, MA

9:00 **The functional significance of changes in cytoskeletal intermediate filament composition during the epithelial-to-mesenchymal transition: Vimentin is more than a biomarker**
Robert D. Goldman, Northwestern University, Chicago, IL

9:30 **Insurance against EMT: MiR-200c directly targets multiple nonepithelial genes***
Erin N. Howe, University of Colorado at Denver, Aurora, CO

9:45 **EMT-induced tubulin detyrosination can be inhibited with parthenolide, reducing microtentacles and the lung retention of circulating breast tumor cells***
Stuart S. Martin, University of Maryland, Baltimore, MD

10:00 a.m.-10:30 a.m. Coffee Break

10:30 a.m.-12:30 p.m. Session 6
EMT and Cancer Stem Cells
Chairperson: Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

10:30 **Stem cells and cancer: Two faces of self renewal**
Michael F. Clarke, Stanford University, Stanford, CA

11:00 **The epithelial-mesenchymal transition and the stem-cell state**
Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

11:30 **Residual tumors after therapy display mesenchymal and tumor-initiating properties**
Jenny Chang, Baylor College of Medicine, Houston, TX

12:00 **Prosurvival signaling network switching through epithelial-mesenchymal transitions**
John D. Haley, OSI Pharmaceuticals, Inc., Farmingdale, NY

*Indicates proffered presentation from selected abstracts